Key Takeaways
- Revenue fell 20% YoY: U.S. tariffs, Chinese dumping in Dimer Acid, and weak domestic paint demand combined to compress volumes and margins in a single quarter.
- Dimer Acid margin floor reached: Management called further EBITDA margin decline below the current 3.8–4% range "highly unlikely," but a return to double digits requires three separate conditions to align simultaneously.
- U.S. exports went to zero: The 50% tariff made Dimer Acid and Isostearic Acid exports to the U.S. "as good as nil" this quarter, removing a substantial volume that had shipped in the July–September 2024 quarter.
- CFO transition underway: Rajen Jhaveri departs November 14; Bhavesh Shah (from Arvind Limited) takes over November 15, with an internal elevation for the Company Secretary role.
- What to watch next quarter: Whether the animal feed trial run begins in December–January as planned, any progress on U.S.–India tariff negotiations, and whether the Isostearic Acid export ramp-up clears its European regulatory hurdle.
Revenue Breakdown: What Drove the Decline
- U.S. tariff shock: The 50% U.S. tariff on certain Indian chemical products hit Fairchem's key offerings directly, temporarily halting export business and creating near-term uncertainty in international trade flows.
- Paint sector weakness: Domestic paint demand weakened, leading to lower off-take from one major customer and pulling Linoleic Acid's revenue share down from 40% to 33%.
- Dimer Acid volume shift: Dimer Acid share rose from 27% to 33% as an internal swap occurred between the two products, but this came with severe margin pressure from Chinese competition.
- Export composition: The 9% export share that remained was mainly Isostearic Acid to Europe and other non-U.S. markets; U.S. exports of both Dimer Acid and Isostearic Acid were "as good as nil" this quarter.
- Isostearic Acid delay: The expected ramp-up in exports to non-U.S. markets has been delayed as Fairchem works through regulatory compliance processes mandated by two major European producers.
Dimer Acid: The Margin Squeeze Mechanics
- Chinese competition sets the price: Fairchem prices Dimer Acid marginally below the landed cost of Chinese imports plus non-cenvatable customs duty to retain roughly 65% market share, a formula that compresses selling prices when Chinese producers are aggressive.
- Raw material cost stays elevated: Soya acid oil byproduct pricing has its own demand-supply economics, and refineries can keep prices artificially elevated when there is more than one buyer competing for the same raw material.
- No backward integration path: Fairchem cannot integrate into refining because the raw material represents only 1.25% of refinery output; selling the remaining 98% edible oil in consumer markets is outside the company's expertise.
- Competitor landscape is fragmented: Three to four smaller, "quite disorganized" competitors in MP and other states also compete for the same acid oil raw material, preventing Fairchem from exercising buyer power despite being the only Dimer Acid manufacturer.
- Government unlikely to intervene: Fairchem made a representation to the government regarding Chinese dumping but has not heard back and is "unlikely to get any because we are the only manufacturer of Dimer Acid in India."
Jhaveri: "Historically, what we have been doing is we have been pricing our Dimer Acid at marginally lower price than what is the landed cost of Chinese Dimer Acid plus the non-cenvatable custom duty. So, if that works out to say X rupees, our price would be X minus INR 2 or something like that."
Margin Outlook: The Path Back to Double Digits
- Current floor: Further margin fall below the current 3.8–4% range is "highly unlikely," but the company is operating at a level far below its historical double-digit profile.
- Three conditions for recovery: EBITDA margin will return to double digits only when multiple factors align simultaneously: easing of raw material prices, U.S. export revival of both Dimer Acid and Isostearic Acid, and the animal feed project materializing.
- Timeline hope: Management is hoping for improvement during the January–March 2026 quarter; if not, it should "certainly be in place by April 2026."
- Previous guidance abandoned: The December 2024 PPT guidance of ₹1,000 crore revenue and 23% EBITDA margin was based on April 2024 assumptions that "no more hold good."
- Raw material is not the only driver: Margin compression comes from reduced selling prices forced by tariffs and Chinese competition, which on a pro rata basis increases raw material cost as a percentage of sales even if absolute raw material prices do not rise.
Jhaveri: "All those things will have to fall in place simultaneously... easing of some raw material prices, U.S. export revival of both Dimer Acid and Isostearic Acid and this our animal feed thing, which we are planning. All these things should fall in line. And that would surely then be our EBITDA margin would be in double digits, 100%."
New Products: Animal Feed and the Pipeline
- Two animal feed products in development: One for the domestic market with first commercial production trial expected by March 2026 or at most during the April–June 2026 quarter; another for exports to Europe and the USA with trial runs possible during December 2025 or January 2026.
- Export product faces longer approval: The animal feed product meant for exports will take further time to get regulatory approval, and management finds the timeline difficult to predict.
- Margin profile is lower than Isostearic Acid: The animal feed product is a commodity with demand in several thousands of tons, so its margin profile will not match Isostearic Acid, which is a specialized product with only two European manufacturers.
- Another raw material or product remains in the pipeline: Still under development, with first commercial production trial targeted for March 2026 or the April–June 2026 quarter at the latest.
- Commercial production timing: Animal feed commercial production should fall in place during the April–June 2026 quarter, with gradual ramp-up thereafter.
U.S. Market: Tariff Dependency and Structural Opportunity
- Tariff resolution is the gate: Once India closes a deal with the U.S. at a "rational tariff of, say, 10% or 15%," Fairchem will be "back in game" for Dimer Acid exports.
- U.S. structural need exists: U.S. manufacturers need Dimer Acid, and one U.S. plant has already closed, making the market dependent on India and China for supply.
- Substantial volume lost: Substantial Dimer Acid exports to the USA were made in the July–September 2024 quarter but could not continue this quarter due to tariff issues, creating a sharp year-over-year hole.
- No guidance during uncertainty: Management explicitly declined to give guidance, citing the current period of unsettled tariffs, ongoing regulatory compliance work for Isostearic Acid, and the animal feed project's development stage.
Jhaveri: "It is unfortunate. It is more torturous for us than for you. We understand that it is torturous for all the investors, but you will also appreciate that it will be double the thing for us because we remain committed on that and we need to deliver on this. So, the onus is more on us as of now."
Competitive and Market Structure
- Only Dimer Acid manufacturer, but not alone in raw material: Fairchem is the sole Indian manufacturer of Dimer Acid but not the only manufacturer of Linoleic Acid; three to four other manufacturers of Soya Fatty Acid compete for the same acid oil raw material.
- Market data is unavailable: The government discontinued disclosure of quantity details about a decade ago, listed companies are not required to disclose quantity data, and unlisted company data is not publicly accessible, making market share calculations impossible. [13–14]
- Buyer behavior adds opacity: Large and multinational buyers may purchase from multiple suppliers including the unorganized sector, blending products to meet specifications at lower cost, and they "would not disclose these details" to Fairchem.
- Chinese process is similar: Chinese manufacturers follow "more or less the same thing," buying from Chinese edible oil refiners, so there is no structural cost advantage Fairchem can replicate.
- Capital-light industry limits shakeout: Fatty acid manufacturing is not capital-intensive, unlike steel, so margin pressure does not necessarily force smaller competitors to shut down and consolidate the market.
Jhaveri: "These manufacturers, these refineries also know that the soya acid oil, if there is more than one buyer, they can always keep the prices at an artificially elevated level compared to what was prevailing in earlier years or earlier quarters."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Animal feed trial (domestic) | First commercial production trial | March 2026 or at most April–June 2026 quarter |
| Animal feed trial (exports) | Trial runs for export-grade product | December 2025 or January 2026 |
| Animal feed commercial production | Commercial production begins, gradual ramp-up | April–June 2026 quarter |
| Margin recovery | Improvement in EBITDA margin | Hoping for January–March 2026 quarter; if not, "certainly by April 2026" |
| Double-digit EBITDA margin | Return to double digits | When raw material eases, U.S. exports revive, and animal feed materializes simultaneously |
| U.S. export revival | Dimer Acid exports resume | When India closes a tariff deal with U.S. at 10–15% |
| Isostearic Acid export ramp-up | Steady phased growth in non-U.S. exports | Once European regulatory registrations are completed |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹112 cr, declined 20% YoY |
| EBITDA | ₹4 cr, declined 52% YoY |
| EBITDA margin | 3.77% |
| Net profit after tax | ~₹80 lakh, PAT margin 0.72% |
| H1 FY26 revenue from operations | ₹243 cr, declined ~20% YoY |
| H1 FY26 EBITDA | ₹9 cr, declined ~69% YoY |
| H1 FY26 EBITDA margin | 3.87% |
| H1 FY26 net profit after tax | ₹2 cr, declined ~89% YoY |
| Domestic sales share | 91.22% of total revenue |
| Export share | 8.78% of total revenue |
| Volume processed | 11,492 metric tons |
| Volume sold | 10,062 metric tons |
| Linoleic Acid revenue share | 33%, down from 40% in Q1 FY26 |
| Dimer Acid revenue share | 33%, up from 27% in Q1 FY26 |
| Chinese Dimer Acid price decline | More than 25% over the last 24 months |
| Dimer Acid market share | ~65% retained in India |
| Basic custom duty on imported Dimer Acid | 7.5% |